Every 10-Q that Cardinal Health, Inc. (CAH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CAH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAH filings page.
Cardinal Health reported strong growth for the quarter ended March 31, 2026. Revenue rose 11% to $60.9 billion, driven mainly by higher branded and specialty pharmaceutical sales, including increased GLP‑1 demand. Pharma segment revenue reached $56.1 billion, while Other grew 31% on at‑Home Solutions, Nuclear and Precision Health, and OptiFreight®.
GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment at the Navista & ION oncology MSO unit and the absence of prior‑year litigation recoveries. However, non‑GAAP operating earnings rose 18% to $956 million, and non‑GAAP diluted EPS increased 35% to $3.17, reflecting acquisitions of MSO platforms and Advanced Diabetes Supply Group and a strong generics program.
The company completed the $1.9 billion Solaris Health acquisition, helping lift goodwill to $11.4 billion, and ended the period with $3.9 billion of cash and equivalents. Liquidity is supported by unused credit facilities and a receivables program, while Cardinal continues making opioid settlement payments and investing in share repurchases and dividends. Tariffs remain a headwind, particularly in Global Medical Products and Distribution, where segment profit for the quarter declined 36%.
Cardinal Health delivered strong growth for the quarter ended December 31, 2025. Revenue rose 19% to $65.6 billion, driven mainly by branded and specialty pharmaceuticals, while six-month revenue increased 21% to $129.6 billion. GAAP operating earnings grew 29% to $707 million and non-GAAP operating earnings were up 38% to $877 million.
GAAP diluted EPS increased 19% to $1.97, with non-GAAP diluted EPS up 36% to $2.63, reflecting contributions from recent acquisitions and stronger pharma and generics performance, partly offset by higher interest expense. The company completed the $1.9 billion Solaris Health acquisition, continued integrating other MSO platforms, repurchased $758 million of shares, paid $251 million in dividends, and ended the quarter with $2.8 billion in cash and $9.0 billion of long-term obligations while carrying $4.3 billion in opioid-related accruals.
Cardinal Health (CAH) reported strong first‑quarter results for the period ended September 30, 2025. Revenue rose 22% to $64.0 billion, driven by branded and specialty pharmaceutical sales. GAAP operating earnings increased 18% to $668 million, while non‑GAAP operating earnings grew 37% to $857 million.
GAAP diluted EPS was $1.88 (up 11%) and non‑GAAP diluted EPS was $2.55 (up 36%), reflecting contributions from recently acquired MSO platforms and Advanced Diabetes Supply. Segment profit improved across the board: Pharma up 26% to $667 million, Global Medical up to $46 million, and Other up 60% to $166 million. GLP‑1 demand boosted sales but had limited profit impact due to mix.
Liquidity strengthened with $4.6 billion in cash and $973 million provided by operations, including $403 million in opioid‑related payments. The company issued $1.0 billion of new notes (4.5% due 2030; 5.15% due 2035), repaid $500 million of 2025 notes, and executed a $375 million accelerated share repurchase. CAH announced a definitive agreement to acquire Solaris Health for approximately $1.9 billion in cash plus an estimated $500 million in Specialty Alliance units, to be reported within the Pharma segment upon closing.